Back to Trades
Sell4
MADRIGAL PHARMACEUTICALS, INC.
MDGL
Total Value
$14.8M
Net $8.0M sold
Sales
$8.0M
11 transactions
Company Information
- Company Name
- MADRIGAL PHARMACEUTICALS, INC.
- Ticker Symbol
- MDGL
- CIK
- 0001157601
Insider Information
- Name
- BATE KENNETH
- Role
- Director
- Location
- WEST CONSHOHOCKEN, PA
Director
Filing Details
- Filing Date
- Nov 7, 2025
- Transaction Date
- Nov 5, 2025
- Accession Number
- 0001628280-25-050668
- Form Type
- 4
- Net Trading Amount
- -$8.0M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Nov 5, 2025 | Common Stock | 5,470 | $9.45 | Exercise | $51.7K |
| Nov 5, 2025 | Common Stock | 10,000 | $303.79 | Exercise | $3.0M |
| Nov 5, 2025 | Common Stock | 1,105 | $280.04 | Exercise | $309.4K |
| Nov 5, 2025 | Common Stock | 1,763 | $480.24 | Sale | $846.7K |
| Nov 5, 2025 | Common Stock | 3,259 | $481.13 | Sale | $1.6M |
| Nov 5, 2025 | Common Stock | 1,284 | $482.41 | Sale | $619.4K |
| Nov 5, 2025 | Common Stock | 2,069 | $483.41 | Sale | $1.0M |
| Nov 5, 2025 | Common Stock | 1,931 | $484.78 | Sale | $936.1K |
| Nov 5, 2025 | Common Stock | 1,008 | $485.54 | Sale | $489.4K |
| Nov 5, 2025 | Common Stock | 827 | $486.73 | Sale | $402.5K |
| Nov 5, 2025 | Common Stock | 2,775 | $487.49 | Sale | $1.4M |
| Nov 5, 2025 | Common Stock | 696 | $489.09 | Sale | $340.4K |
| Nov 5, 2025 | Common Stock | 933 | $489.95 | Sale | $457.1K |
| Nov 5, 2025 | Common Stock | 30 | $490.98 | Sale | $14.7K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Nov 5, 2025 | Derivative | 5,470 | $9.45 | Exercise | $51.7K |
| Nov 5, 2025 | Derivative | 10,000 | $303.79 | Exercise | $3.0M |
| Nov 5, 2025 | Derivative | 1,105 | $280.04 | Exercise | $309.4K |
Footnotes
- (F1)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.66 to $480.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
- (F2)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.71 to $481.68, inclusive.
- (F3)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.84 to $482.71, inclusive.
- (F4)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.00 to $483.92, inclusive.
- (F5)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.02 to $485.015, inclusive.
- (F6)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.10 to $486.04, inclusive.
- (F7)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.10 to $486.99, inclusive.
- (F8)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.13 to $488.09, inclusive.
- (F9)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $488.74 to $489.49, inclusive.
- (F10)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $489.74 to $490.7125, inclusive.
- (F11)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $490.7625 to $491.42, inclusive.
- (F12)The shares underlying this option are fully vested and exercisable.